Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
A tendency to increase the inflammatory markers IL-6 (p = 0.069) and MCP-1 (p = 0.067) was observed in those patients suffering from MS. An increase in the cardiovascular risk markers PAI-1 (p = 0.007) and triglycerides/HDL cholesterol ratio (p < 0.0001) was also found in the MS group.
|
30924020 |
2019 |
Metabolic Syndrome X
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Comparison of gene expression pattern between CAD and MetS revealed significantly higher expression of leukotriene genes - arachidonate 5-lipoxygenase (ALOX5), arachidonate 5-lipoxygenase activating protein (ALOX5 AP), leukotriene A4 hydrolase (LTA4H) and leukotriene C4 synthase (LTC4S), and lower expression of NF-κB, interleukin 1 beta (IL-1β), monocyte chemoattractant protein-1 (MCP-1/CCL2) and signal transducer and activator of transcription 3 (STAT3) genes in CAD.
|
29067980 |
2017 |
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MCP-1 allele and genotype were significantly associated with MetS.
|
25639755 |
2015 |
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition to increased expression of downstream signaling mediators RIPK2 and NF-κB p65 nuclear translocation, there was remarkably higher release of monocyte chemotactic protein1 (MCP-1), interleukin (IL)-6, and IL-8 in MetS versus controls following priming of the isolated adipocytes with NOD1 ligand iE-DAP.
|
26052894 |
2015 |
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
FAM5C also corresponds directly with the inflammatory biomarker monocyte chemoattractant protein 1 (MCP-1) and metabolic syndrome.
|
22013132 |
2013 |
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum MCP-1 (P = 0·02), eotaxin-1 (P = 0·02) and MIP-1β (P = 0·03), CRP (P < 0·001) and IL-6 (P = 0·006) were significantly increased in metabolic syndrome in comparison with lean controls.
|
23170936 |
2013 |
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
Neutralization of the pro-inflammatory pathway Fas/FasL completely prevented vascular hypo-reactivity and the ability of MetS microparticles to enhance both inducible NO-synthase and monocyte chemoattractant protein-1 (MCP-1).
|
22110764 |
2011 |
Metabolic Syndrome X
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The MCP-1 -2518G allele may be contributing to atherosclerosis and CAD by conferring an increased risk to metabolic syndrome and/or obesity.
|
19450143 |
2009 |
Metabolic Syndrome X
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Enhanced levels of MCP1 resulting from reduced IRS2 expression and accompanying defects in AKT2 and Ras/ERK1/2 signaling pathways may contribute to accelerated atherosclerosis in MetS states.
|
18802016 |
2008 |
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
CTD_human |
Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients?
|
18486454 |
2008 |
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
BEFREE |
This is the first study to investigate the associations of MCP-1 SNPs with MetS.
|
17322498 |
2007 |
Metabolic Syndrome X
|
0.400 |
Biomarker
|
disease |
CTD_human |
This paradigm supports the notion that elevated CCL2 levels in visceral adipose tissue associated with Metabolic Syndrome is a chemotactic niche, whereby fibrocytes can home to and differentiate into adipocytes to perpetuate its tissue formation.
|
16188961 |
2005 |